The migraine therapy market comprises an array of prescription acute and prophylactic treatments and fosters a large and dynamic pipeline. We anticipate the launch of several new brands, including novel triptan and DHE reformulations and promising nontriptan alternatives. Among them are Eli Lilly’s 5-HT1F receptor agonist lasmiditan and two oral calcitonin gene-related peptide (CGRP) receptor antagonists—Allergan’s ubrogepant and Biohaven’s rimegepant. They will support future growth in the large acute segment. However, it is the 2018 launch of three premium-priced anti-CGRP MAbs (a fourth is expected in 2020) for migraine prophylaxis in both episodic and chronic migraineurs that will be the main driver of multibillion-dollar sales growth of this market. These drugs follow in the footsteps of Allergan’s Botox (approved for chronic migraine), which has proven the commercial opportunity that new, valued brand alternatives can seize in the otherwise generic prophylaxis segment.

Questions Answered:

  • How will Amgen / Novartis’s Aimovig, Teva’s Ajovy, Eli Lilly’s Emgality, and Alder’s eptinezumab compete with one another and with established prophylactic therapies as their marketers vie for patient share? How will the launch of two oral CGRP antagonists impact the migraine prophylaxis market?
  • Will novel NMEs lasmiditan, ubrogepant, and rimegepant gain a foothold in the heavily generic acute segment dominated by triptans?
  • How will novel triptan and DHE reformulations, including Zosano’s Qtrypta and Impel NeuroPharma’s INP-104, compete for patient share with existing branded and generic non-oral options in the small niche patient population in need of non-oral alternatives?

Product Description:

Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.

Table of contents

  • Disease Landscape & Forecast
    • Key Updates
      • September 2019
      • April 2019
      • November 2018
      • September 2018
    • Market Outlook
      • Key Findings
      • Market Drivers and Constraints
        • What Factors Are Driving the Market for Migraine?
        • What Factors Are Constraining the Market for Migraine?
      • Segment-Specific Trends
        • Acute Treatment of Migraine
        • Migraine Prophylaxis
        • Episodic and Chronic Migraine
      • Drug-Class-Specific Trends
        • 5-HT1B/1D Receptor Agonists
        • Ergot Derivatives
        • 5-HT1F Receptor Agonists
        • Other Acute Therapies
        • Anti-CGRP Monoclonal Antibodies
        • CGRP Receptor Antagonists
        • Other Prophylactic Therapies
      • Alternative Market Scenarios
    • Forecast
      • Market Forecast Assumptions
      • Market Forecast Dashboard
    • Etiology and Pathophysiology
      • Disease Overview
      • Genetic Factors
      • Environmental Factors: Migraine Triggers
      • Key Pathways and Drug Targets
    • Epidemiology
      • Key Findings
      • Epidemiology Populations
        • Total Migraine Prevalence
        • Episodic Migraine Prevalence
        • Chronic Migraine Prevalence
        • Frequency of Episodic Migraine Attacks
        • Total Episodic Migraine Events
        • Diagnosed Prevalent Cases of Migraine
        • Drug-Treated Cases of Migraine
    • Current Treatment
      • Key Findings
      • Treatment Goals
      • Key Current Therapies: Acute Treatment
        • Overview
        • 5-HT1 Receptor Agonists
        • Dihydroergotamine Mesylate
        • Prescription NSAIDs and Non-Narcotic Analgesics
        • Narcotic Prescription Analgesics
      • Key Current Therapies: Prophylactic Treatment
        • Overview
        • Antiepileptic Drugs
        • Neuromuscular Blocking Agents
        • Anti-CGRP Monoclonal Antibodies
        • Beta Blockers
        • Antidepressants
        • Calcium-Channel Blockers
      • Medical Practice
        • Overview
        • Treatment Guidelines
        • Region-Specific Treatment Practices
    • Unmet Need Overview
      • Current and Future Attainment of Unmet Needs in Migraine
    • Emerging Therapies
      • Key Findings
      • Key Emerging Therapies
        • Notable Developments in the Late-Phase Pipeline for Migraine
        • Triptan Reformulations
        • Ergot Derivatives
        • 5-HT1F Receptor Agonists
        • COX-2 Inhibitors
        • Anti-CGRP Monoclonal Antibodies
        • CGRP Receptor Antagonists
      • Early-Phase Pipeline Analysis
        • Notable Developments in the Early-Phase Pipeline for Migraine
    • Access & Reimbursement Overview
      • Region-Specific Reimbursement Practices
        • United States
        • EU5
        • Japan
      • Looking for More?
    • Methodology
      • Bottom-Up Forecasting Overview
        • Patient Populations
        • Drug-Specific Assumptions
      • Bottom-Up Forecast Assumptions
        • General Sources of Data
        • Agents Included in Our Market Analysis
        • General Statements About Pricing
        • Dosing, Days of Therapy, and Compliance
        • Generic Erosion
        • Out-Year Forecasting
        • Emerging Therapy Prices
      • Primary Market Research
        • Experts Interviewed
    • Appendix
      • Migraine Bibliography

Author(s): Jonathan Searles; Ruchita Kumar, Ph.D; Shilpa Thakur

Jonathan ;Searles is a Senior Director in the CNS/Ophthalmology unit at DRG, overseeing the neurology research stream. Prior to joining DRG, ;Searles received a degree, summa cum laude, from Brandeis University; during this time, Mr. Searles conducted research projects at the Harvard University Peabody Museum and at Brandeis.

Ruchita has joined as a Lead Analyst in the Central Nervous System and Ophthalmology team at Decision Resources Group. She comes with eight years of experience in handling various types of commercial assessment projects. She has worked on variety of opportunity assessment and market intelligence projects involving preparation of disease narratives, epi-based forecasts, patent landscapes, social media analysis and building brand performance reports across different therapy areas. She earned a in design and development of modified release dosage forms of anti-diabetic drugs from the University Institute of Pharmaceutical Sciences, Panjab University, Chandigarh.

Shilpa Thakur is a medical graduate with a from the Postgraduate Institute of Medical Education and Research with a specialization in epidemiology and biostatistics. She specializes in developing epidemiological forecasts for the multiple indications within the DRG syndicated portfolio. Prior to joining Decision Resources, she monitored HIV sentinel surveillance 2016-2017 in Himachal Pradesh. She also has worked on to see the patterns of Antimicrobial resistance in India.  

Related Reports

Migraine | Emerging Therapies | Aimovig-Migraine Prevention Wave 3 (US)

Market Outlook The migraine prophylaxis therapy market is poised for disruption following the launch of three anti-CGRP MAbs in the United States in 2018, with a fourth...

View Details

Migraine | Emerging Therapies | Ajovy and Emgality - Migraine (Wave 2) US

Market Outlook The migraine prophylaxis therapy market is poised for disruption following the launch of three anti-CGRP MAbs in...

View Details

Migraine | Current Treatment | Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis (Prophylaxis)

Market Outlook According to DRG epidemiology, more than 35 million people in the United States suffer from migraines. Despite being u...

View Details

Migraine | Emerging Therapies | Ajovy and Emgality - Migraine (Wave 3) US

Coming Soon – November 2019 Market Outlook The migraine prophylax...

View Details